Intravenous Immunoglobulin Market Report Scope & Overview:

The Intravenous Immunoglobulin Market was valued at USD 14.98 Billion in 2025 and is expected to reach USD 30.83 Billion by 2035, growing at a CAGR of 7.49% from 2026 to 2035.

The intravenous immunoglobulin market is still being propelled by the rise in the number of cases of immunodeficiency disorders, autoimmune disorders, and neurological disorders that require treatment through immunoglobulins. The increasing demand is being propelled by growing awareness of the diseases, improving diagnosis of the diseases, and increased usage of immunoglobulins in hospitals and specialty centers. The supply side dynamics will continue to depend on plasma collection and plasma processing because intravenous immunoglobulins come from human plasma. There have been efforts by the players in the industry to set up manufacturing plants and collect plasma as the demand for treatments increases.

Takeda Pharmaceutical Company received United States Food and Drug Administration approval in June 2025 for an expanded indication of GAMMAGARD LIQUID, broadening the therapeutic applications available to physicians treating patients with primary immunodeficiency and related immune disorders.

Market Size and Forecast

• Market Size in 2026E: USD 16.10 Billion
• Market Size by 2035: USD 30.83 Billion
• CAGR: 7.49% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

To Get more information Intravenous Immunoglobulin Market - Request Free Sample Report

Intravenous Immunoglobulin Market Trends

• Continuous expansion of plasma collection and fractionation capacity continues supporting rising global treatment demand.
• Rising clinical use of IVIG beyond primary immunodeficiency continues broadening the therapeutic opportunity landscape.
• Expanding neurological indications, including chronic inflammatory demyelinating polyneuropathy, continue widening addressable patient populations.
• Specialty clinics focused on neurology and immunology continue streamlining infusion protocols and improving patient monitoring capability.
• Manufacturers continue developing subcutaneous immunoglobulin alternatives while preserving intravenous formulations for acute, high-dose requirements.

The United States Intravenous Immunoglobulin Market Outlook

The United States Intravenous Immunoglobulin Market was valued at USD 7.71 Billion in 2025 and is expected to reach USD 16.58 Billion by 2035, growing at a CAGR of 7.95% from 2026 to 2035.

Nevertheless, the market of the United States still enjoys a rich presence of prominent medical establishments, research centers, and educational institutions that contribute to widespread access to IVIG therapy, especially in the Northeast market segment comprising New York, New Jersey, Massachusetts, and Pennsylvania. Top firms operating in the American market continue focusing on growth through various means, such as introduction of new products, investments in R&D, mergers and acquisitions, and innovations in current IVIG therapy, while 100 percent import duties on the landed cost of IVIG therapy products implemented in October 2025 have significantly increased costs of foreign IVIG products.

KabaFusion partnered with GC Biopharma U.S. in July 2024 to strengthen distribution and supply chain capability for immunoglobulin therapies, supporting patients across the United States requiring reliable access to IVIG treatment.

Intravenous Immunoglobulin Market Segmentation Analysis

• By Product Type, the IgG segment held approximately 74.75% share in intravenous immunoglobulin market in 2025, while the recombinant immunoglobulins segment is the fastest growing.
• By Application, the immunodeficiency diseases segment held the largest share in intravenous immunoglobulin market in 2025, while the neurological disorders segment is the fastest growing.
• By Distribution Channel, the hospital pharmacies segment held approximately 57.10% share in intravenous immunoglobulin market in 2025, while the specialty pharmacy segment is the fastest growing.
• By End-User, the hospitals segment held the largest share in intravenous immunoglobulin market in 2025, while the specialty clinics segment is the fastest growing, with a CAGR of approximately 8.61%.

By Product Type, IgG segment dominates the intravenous immunoglobulin market, while recombinant immunoglobulins grows fastest

The IgG segment held approximately 74.75% of total market revenue in 2025, as its pharmacology suits both replacement and immunomodulatory therapy across the broadest range of immune disorders. That pharmacological versatility continues to keep IgG firmly at the top of the broader product type segmentation across nearly every major IVIG application worldwide.

The recombinant immunoglobulins segment is projected to grow at the fastest CAGR during the forecast period, as manufacturers continue developing next-generation products that reduce dependence on donor plasma supply while maintaining therapeutic efficacy. Continued research and development investment in recombinant production technology continues to push this product type category's growth rate ahead of the broader product type segmentation.

By Application, immunodeficiency diseases segment dominates the intravenous immunoglobulin market, while neurological disorders grows fastest

The application segmentation was dominated by the immunodeficiency diseases segment in 2025 due to the established use of the product as a first-line therapy for various immune diseases. Awareness and the diagnosis programs are contributing to demand sustainability through an increase in the number of patients suffering from such conditions and successful treatment with IVIG.

The neurological disorders segment is projected to grow at the fastest CAGR during the forecast period, supported by expanding clinical use of IVIG in conditions including chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and Guillain-Barre syndrome. Growing recognition of IVIG efficacy in chronic neuromuscular diseases continues accelerating adoption as neurologists incorporate evidence-based protocols into long-term management strategies, pushing this application segment's growth rate ahead of the broader application segmentation.

By Distribution Channel, hospital pharmacies segment dominates the intravenous immunoglobulin market, while specialty pharmacy grows fastest

The hospital pharmacies segment held approximately 57.10% of total market revenue in 2025, supported by the established infrastructure that hospitals maintain for administering plasma-derived therapies requiring careful clinical supervision. That established clinical infrastructure continues to keep hospital pharmacies firmly at the top of the broader distribution channel segmentation across the majority of IVIG treatment episodes worldwide.

The specialty pharmacy segment is projected to grow at the fastest CAGR during the forecast period, as specialty pharmacies increasingly facilitate treatment at home, allowing patients to receive IVIG therapy outside traditional hospital settings. That home-based treatment convenience continues to push this distribution channel's growth rate ahead of the broader distribution channel segmentation.

By End-User, hospitals segment dominates the intravenous immunoglobulin market, while specialty clinics grows fastest

The hospitals segment held the largest share of the end-user segmentation in 2025, anchored by the comprehensive clinical infrastructure and specialist availability required for administering acute, high-dose IVIG treatment for critical immune disorders. That established clinical infrastructure continues to keep hospitals firmly at the top of the broader end-user segmentation.

The specialty clinics segment is projected to grow at the fastest CAGR of approximately 8.61% during the forecast period, as clinics focused on neurology and immunology continue streamlining infusion protocols, improving patient monitoring, and delivering an improved overall patient experience. That improved treatment experience continues to push this end-user segment's growth rate ahead of the broader end-user segmentation.

Regional Analysis

North America Intravenous Immunoglobulin Market Insights

North America held the largest share of the global intravenous immunoglobulin market in 2025, supported by well-established reimbursement pathways, high per-capita spending, and IVIG's role as first-line treatment for several critical immune disorders across the region. Strong adoption of advanced intravenous immunoglobulin products and a rising number of patient diagnoses continued reinforcing this leadership position throughout the year.

The United States made up about 84.90% of regional revenue due to being home to key producers of plasma-derivatives therapies and healthcare reimbursement systems. Canada was contributing a relatively lower percentage of regional revenue, yet one that has been growing with time owing to its increasing adoption of immunotherapy. North America continued to lead other regions in this market.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Intravenous Immunoglobulin Market Insights

Europe held a substantial share of the global intravenous immunoglobulin market in 2025, supported by well-established national health insurance coverage and strong plasma collection infrastructure across the continent. Germany accounted for roughly 27.30% of regional revenue, supported by its concentration of plasma fractionation facilities and comprehensive healthcare infrastructure.

France, the United Kingdom, and Italy followed a broadly similar trajectory, as continued investment in plasma collection and fractionation capacity extended IVIG availability across the continent's largest healthcare markets. Continued regulatory support for expanding immunoglobulin therapy access is expected to keep supporting steady European demand through the remainder of the forecast period.

Asia Pacific Intravenous Immunoglobulin Market Insights

Asia Pacific was the fastest-growing region in the global intravenous immunoglobulin market, supported by rapid healthcare access gains and policy reform that continue propelling regional demand at a pace considerably faster than more mature Western markets. Larger reimbursement pools and an aging population continued driving regional demand growth throughout the year.

China accounted for roughly 36.50% of regional revenue, supported by expanding domestic plasma collection infrastructure and growing immunotherapy awareness. Japan and South Korea contributed significant additional regional demand through their own advanced healthcare systems and plasma fractionation capability, reinforcing Asia Pacific's position as the clear growth leader in this market.

MEA & Latin America Intravenous Immunoglobulin Market Insights

The Middle East and Africa region recorded steady growth in IVIG adoption in 2025, driven by expanding healthcare infrastructure investment and growing government support for immunotherapy access across the Gulf states in particular. The UAE accounted for roughly 26.40% of regional revenue, supported by national healthcare modernization strategies and rising demand for advanced immunoglobulin therapies.

Latin America expanded at a comparable pace, led by Brazil at roughly 37.30% of regional revenue, where growing healthcare infrastructure investment continued to support category growth. Mexico and Argentina followed a similar trajectory as regional immunotherapy adoption expanded further through the remainder of the forecast period.

Growth Drivers: Rising Immunodeficiency Prevalence and Expanding Neurological Applications

The increasing prevalence of primary immunodeficiency disorders, autoimmune diseases, and neurological conditions that require immunoglobulin-based therapies continues to be the central force behind intravenous immunoglobulin market growth. Growing disease awareness, improving diagnosis rates, and expanding use of immunoglobulin therapies across hospitals and specialty care centers continue reinforcing structural demand growth across nearly every major regional market worldwide.

Increasing awareness and advancements in immunotherapy, coupled with an aging population more susceptible to immune-related conditions, continue to further fuel market growth. Rising clinical use of IVIG beyond primary immunodeficiency into neurological and autoimmune disorders continues reinforcing sustained market expansion through the forecast period.

Restraints: Plasma Supply Dependency and Tariff-Driven Cost Pressure

Supply dynamics remain dependent on plasma collection and plasma processing capacity, given that intravenous immunoglobulin products are derived from human plasma, creating genuine supply constraints when donor recruitment cannot keep pace with rising demand. That plasma supply dependency continues requiring sustained investment in donor recruitment campaigns and fractionation capacity expansion.

The high cost of IVIG therapy, combined with a one hundred percent United States tariff on imported finished IVIG products effective since October 2025, continues sharply raising landed costs for non-domestic brands and forcing payers to reconsider preferred supplier lists. That tariff-driven cost pressure continues complicating supply chain and procurement planning across the broader intravenous immunoglobulin market.

Opportunities: Subcutaneous Alternative Development and Emerging Market Expansion

Continued development of subcutaneous immunoglobulin alternatives presents substantial opportunity for manufacturers positioned to ease supply pressure while preserving intravenous formulations for acute and high-dose requirements. Manufacturers capable of delivering genuinely differentiated subcutaneous products stand to capture a growing share of demand as this technology continues maturing.

Rising demand in emerging economies presents a further significant growth avenue, as expanding reimbursement pools and improving healthcare access continue extending IVIG availability to previously underserved patient populations. Manufacturers capable of establishing reliable supply chains in these developing markets stand to capture meaningful new revenue streams through 2035.

Recent Developments:

• 2025: CSL Behring continued expanding its plasma collection network and fractionation capacity, reinforcing its position as the market leader holding over twenty-two point five percent global share.
• 2025: Grifols continued advancing its immunoglobulin production technology, strengthening its position among the top five global suppliers through extensive plasma collection and fractionation infrastructure.
• 2025: Octapharma continued investing in expanded plasma processing capacity, targeting growing global demand for both intravenous and subcutaneous immunoglobulin therapies.

Intravenous Immunoglobulin Market key players are:

• CSL Behring
• Grifols S.A.
• Takeda Pharmaceutical Company Limited
• Kedrion Biopharma
• Octapharma AG
• Baxter International Inc.
• Biotest AG
• LFB Biotechnologies SAS
• Bio Products Laboratory Ltd.
• China Biologic Products Holdings Inc.
• Hualan Biological Engineering Inc.
• ADMA Biologics, Inc.
• Sanquin Plasma Products B.V.
• GC Biopharma Corp.
• Shanghai RAAS Blood Products Co., Ltd.
• Emergent BioSolutions Inc.
• KabaFusion
• Green Cross Corporation
• Bharat Serums and Vaccines Limited
• Prothya Biosolutions

Intravenous Immunoglobulin Market Report Scope :